A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
In 2019, shortly after Buc-ee's opened their first store in Alabama, the company was sued for "setting unfair pump prices", because they were selling gasoline to the customers for less money than it costs to buy and transport it to a retail outlet. While it is common within the United States for larger gas station chains to use a pricing strategy where gas is used as a loss leader to draw customers and encourage the sale of other goods, the practice is banned under Alabama state law. Buc-ee's also lost a Texas Employee Retention Agreement case on appeal in 2017. A year after a trial court ordered a former employee to pay Buc-ee's close to $100,000 in damages and attorney's fees for breaching a "retention agreement," a Texas court of appeals reversed the decision and ordered that Buc-ee's receive nothing for its claims against the former employee. The court reasoned that the contract violated Texas's employment-at-will doctrine and did not meet the Texas non-compete agreement requirements, so it was not enforceable. In 2023, crossover artwork of the Buc-ee's beaver and Hatsune Miku was trending on Twitter. An Austin-based artist claimed responsibility for creating "Bucsune Miku". In response, Buc-ee's sent the artist a cease and desist letter regarding the stickers and the use of the beaver logo. The artist withdrew the stickers.
== See also == Peptidoglycan recognition protein Peptidoglycan recognition protein 1 Peptidoglycan recognition protein 3 Peptidoglycan recognition protein 4 Peptidoglycan Innate immune system Bacterial cell walls
=== Public employee pensions === Pritzker refused to take on the City of Chicago's pension liabilities, believing that would jeopardize Illinois's credit rating. Moody's raised it to one level above "junk" after Illinois passed a balanced budget in 2019. But Pritzker did not reject the possibility of allowing Chicago to pool its pension funds with other parts of the state, and created a task force to find ways to tackle municipalities' ballooning pension debts. Pension funds in Illinois are collectively funded at only 47.8%.
== Example == While performing a biceps curl, the person lifting the weight would start with a 25 pound dumbbell and do as many repetitions as possible without significantly compromising form. Then a 20-pound weight would be used until exhaustion is reached. One could continue to "drop" down as many times as they wish, but usually the weight is not dropped to below fifty percent of their one rep maximum.
=== Displays === StoreDot was founded in 2012 by Doron Myersdorf, Simon Litsyn, and Gil Rosenman, initially developing displays and storage devices based on research by Ehud Gazit. A year later its CEO, Myersdorf, said their peptide-based display technology is ready to be "packed and sold" and its related intellectual property could be sold for 300 million dollars. The displays and storage devices were based on "peptide nanocrystals", and a prototype storage device was made in 2012 that is "three times faster than conventional memory." The company's CEO said the display technology is 20% more power-efficient and 90% less costly to manufacture than OLED, and the displays were ready in 2015 for full-scale manufacturing using existing factories and manufacturing processes, and were to be commercialized by 2016. By 2019 the display technology was spun off into its own company, MolecuLED. As of 2022, MolecuLED had no employees.
Sources: en.wikipedia.org
=== The foetus earrings case === In December 1987, artist Rick Gibson exhibited a pair of earrings made with freeze-dried human foetuses at the Young Unknowns Gallery in London. On 3 December 1987 the earrings were seized by the police. On 11 April 1988, Gibson and the gallery owner Peter Sylveire were formally charged with the common law offences of exhibiting a public nuisance and outraging public decency. This was the first occasion on which the charge of outraging public decency had been preferred in more than 80 years. The trial started on 30 January 1989. On 6 February 1989 the public nuisance charge was dismissed. The defence raised a point of law, that "outraging public decency" was no longer known in law so long after the last occasion on which the charge had been preferred. The judge ruled that it could still be preferred no matter how long the hiatus, provided the facts fitted the offence. On 9 February 1989 the jury found Gibson and Sylveire guilty of outraging public decency. Gibson was fined £500 and Sylveire was fined £300. The defence appealed on the point of the validity of the charge of outraging public decency, which was dismissed by the Court of Appeal, which upheld the trial judge's ruling and went some way to restating the law in this area.
== Treatment == The appearance of tuberous breasts can potentially be changed through surgical procedures, including the tissue expansion method, use of autologous fat grafting and breast implants. Depending on the extent of the tuberous breasts, a surgeon will release the constricted tissue and create a new breast fold. The procedure to change the appearance of tuberous breasts can be more complicated than a regular breast augmentation, and some plastic surgeons have specialist training in tuberous breast augmentation. A less complicated single-stage approach using saline implants can also provide a similar result. As treatment for tuberous breasts is desired for some women, referral for treatment under the National Health Service may be possible in the United Kingdom. For those seeking non-surgical solutions, counseling may be recommended as a way of coming to terms with body image.
232Th is the only primordial nuclide of thorium and makes up effectively all of natural thorium, with other isotopes of thorium appearing only in trace amounts as relatively short-lived decay products of uranium and thorium. The isotope decays by alpha decay with a half-life of 1.40×1010 years, over three times the age of the Earth and approximately the age of the universe. Its decay chain is the thorium series, eventually ending in lead-208. The remainder of the chain is quick; the longest half-lives in it are 5.75 years for radium-228 and 1.91 years for thorium-228, with all other half-lives totaling less than a week. 232Th is a fertile material able to absorb a neutron and undergo transmutation into the fissile nuclide uranium-233, which is the basis of the thorium fuel cycle. In the form of Thorotrast, a thorium dioxide suspension, it was used as a contrast medium in early X-ray diagnostics. Thorium-232 is now classified as carcinogenic.
=== Weight regain === Weight regain is common upon discontinuation of weight loss medications, and long-term therapy may sometimes be required for sustained weight loss. After stopping treatment with GLP-1 agonists such as semaglutide, liraglutide and tirzepatide, people regain on average more than half (50–70%) of the lost weight within 1 year. People return to their previous weight within a year and a half after stopping anti-obesity medications.
==== 2014 ==== In March 2014, Novaya Gazeta reported that 1st platoon of the military unit entered South Ossetia from North Ossetia on the night of 7 August 2008 to defend the Roki tunnel. At 4:00 AM on 7 August, one soldier was killed on the firing position after two shots were heard. According to the official version, the cause of death was suicide. However, the soldier's family and comrades' testimonies dispute the official cause of death. In August 2014, Anatoly Khrulyov, the commander of the 58th Army, said in an interview that at 12:03 a.m. on the night of 8 August 2008, he ordered to open the "alarm" packet containing the operational objective of the 58th Army and the plan to reinforce the peacekeepers in South Ossetia prepared in advance before August 2008. Khruloyv said that Russian troops approached the Gupta bridge in South Ossetia in four hours after "the declaration of war" by Georgia and engaged Georgian troops. Khrulyov said that if he had not contacted the General Staff during the war and received new orders, the 58th Army would have taken Tbilisi.
Sources: en.wikipedia.org
== Synthesis == The synthesis of nanogels can be achieved using a vast array of different methods. However, two critical steps typically included in each method are polymerization and crosslinking, with physical and chemical crosslinking the most common. These steps can be completed concomitantly or in sequential order depending on the synthesis method and eventual nanogel application. Here, several different synthesis mechanisms are described briefly.
By 1986–1987, the Reagan administration increasingly employed public rhetorical challenges that emphasized human rights and political choice as tests of Soviet reform, during which the American president used a symbolic address to gauge the credibility of Gorbachev's agenda. The most overt example occurred when Reagan challenged Gorbachev on June 12, 1987 to go further with his reforms and democratization by tearing down the Berlin Wall. In a speech at the Brandenburg Gate next to the wall, Reagan stated:
Individual quick freezing, usually abbreviated IQF, is a descriptive term for freezing methods used in the food processing industry. The food is in individual pieces, and is frozen quickly. Products commonly frozen with IQF technologies are typically smaller pieces of food, and can include berries, fruits and vegetables both diced or sliced, seafood such as shrimp and small fish, meat, poultry, pasta, cheese and grains. Products that have been subjected to IQF are referred to as individually quick frozen.
=== EC 2.8.1: Sulfurtransferases === EC 2.8.1.1: thiosulfate sulfurtransferase EC 2.8.1.2: 3-mercaptopyruvate sulfurtransferase EC 2.8.1.3: thiosulfate—thiol sulfurtransferase EC 2.8.1.4: tRNA sulfurtransferase EC 2.8.1.5: thiosulfate—dithiol sulfurtransferase EC 2.8.1.6: biotin synthase EC 2.8.1.7: cysteine desulfurase EC 2.8.1.8: lipoyl synthase EC 2.8.1.9: molybdenum cofactor sulfurtransferase EC 2.8.1.10: thiazole synthase EC 2.8.1.11: molybdopterin synthase sulfurtransferase EC 2.8.1.12: molybdopterin synthase EC 2.8.1.13: tRNA-uridine 2-sulfurtransferase EC 2.8.1.14: tRNA-5-taurinomethyluridine 2-sulfurtransferase EC 2.8.1.15: tRNA-5-methyluridine54 2-sulfurtransferase EC 2.8.1.16: L-aspartate semialdehyde sulfurtransferase
This article incorporates public domain material from The World Factbook (2025 ed.). CIA. (country: Honk Kong) Hong Kong from BBC News Key Development Forecasts for Hong Kong from International Futures Hong Kong in Transition (1995–2020) Archived 20 March 2025 at the Wayback Machine, an open access photographic archive of recent Hong Kong history Government
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.